Singer et al. have been described for the selective cyclooxygenase-2 inhibitor lumiracoxib an increased risk of liver disease secondary to lumiracoxib treatment linked to the presence of HLAQA1*0102 allele (OR = 5.0, 95% CI 3.6–7.0) (19). Here, PTGS2 is linked to liver disorder.